文献速递皮肤肿瘤

EZH2与DNA甲基化协同下调黑色素瘤关键抑癌基因及干扰素基因特征

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
PubMed 文献 · J Invest Dermatol · 2020-04-29

该研究利用染色质免疫沉淀测序鉴定组成性活跃EZH2(Y641)突变黑色素瘤中被组蛋白甲基化沉默的关键抑癌基因,并评估这些区域是否同时存在DNA甲基化。基因经EZH2和DNA甲基转移酶抑制剂处理后重表达验证,其表达与患者生存相关;53株黑色素瘤细胞系药敏筛选显示敏感性与IFN-γ和IFN-α基因特征强烈下调相关,且可被EZH2抑制剂逆转。

要点

  • EZH2(Y641)突变黑色素瘤中组蛋白甲基化与DNA甲基化共同沉默抑癌基因和IFN基因特征。
  • EZH2抑制剂可逆转IFN-γ和IFN-α基因特征的下调,敏感性与该特征下调相关。
  • EZH2抑制剂或可靶向免疫冷黑色素瘤,联合检查点抑制剂增强免疫应答。

核心结论

  • EZH2与DNA甲基化协同下调黑色素瘤关键抑癌基因及IFN基因特征,EZH2抑制剂可能对免疫冷黑色素瘤有效并增强检查点抑制剂免疫应答。

研究设计与样本

  • 研究采用染色质免疫沉淀测序鉴定EZH2(Y641)突变黑色素瘤中组蛋白甲基化沉默的关键抑癌基因,并评估DNA甲基化。
  • 基因经EZH2和DNA甲基转移酶抑制剂处理后重表达验证,并在临床数据集中分析其表达与患者生存的相关性。
  • 对53株黑色素瘤细胞系进行药敏筛选,比较敏感与耐药细胞的RNA测序谱并进行通路分析。

主要发现

  • EZH2(Y641)突变黑色素瘤中组蛋白甲基化沉默的关键抑癌基因区域同时存在DNA甲基化。
  • putative EZH2靶基因表达与黑色素瘤患者生存高度相关。
  • 药敏筛选显示敏感性与IFN-γ和IFN-α基因特征强烈下调相关,且可被EZH2抑制剂逆转。

临床怎么用

  • EZH2抑制剂可能优先用于免疫冷黑色素瘤,以诱导直接细胞毒性并增强检查点抑制剂免疫治疗应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The histone methylase EZH2 is frequently dysregulated in melanoma and is associated with DNA methylation and silencing of genes involved in tumor suppression. In this study, we used chromatin immunoprecipitation and sequencing to identify key suppressor genes that are silenced by histone methylation in constitutively active EZH2(Y641) mutant melanoma and assessed whether these regions were also sites of DNA methylation. The genes identified were validated by their re-expression after treatment with EZH2 and DNA methyltransferase inhibitors. The expression of putative EZH2 target genes was shown to be highly relevant to the survival of patients with melanoma in clinical datasets. To determine correlates of response to EZH2 inhibitors, we screened a panel of 53 melanoma cell lines for drug sensitivity. We compared RNA sequencing profiles of sensitive to resistant melanoma cells and performed pathway analysis. Sensitivity was associated with strong downregulation of IFN-γ and IFN-α gene signatures that were reversed by treatment with EZH2 inhibitors. This is consistent with EZH2-driven dedifferentiated invasive states associated with treatment resistance and defects in antigen presentation. These results suggest that EZH2 inhibitors may be most effectively targeted to immunologically cold melanoma to both induce direct cytotoxicity and increase immune responses in the context of checkpoint inhibitor immunotherapy.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Tiffen J, Gallagher SJ, Filipp F, et al. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. J Invest Dermatol. 2020. PMID: 32360600. doi:10.1016/j.jid.2020.02.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。